LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today highlighted commentary from numerous independent i…
STAAR Surgical Addresses Broadwood Partners’ Flawed, Misleading, and Misinformed Claims
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement with respect to the…
Uncategorized
Vertical single-pass four-throw pupilloplasty can manage floppy iris
Intraoperative floppy iris syndrome is a clinical situation encountered during phacoemulsification characterized by loss of iris muscle tone, predominantly seen in patients on alpha-1 receptor antagonist medication.The floppiness of the iris tissue alo…
Uncategorized
DefEYE launches as independent company
DefEYE Inc., previously a subsidiary of Verséa Health operating as Verséa Ophthalmics, announced its launch as an independent company, according to a press release.DefEYE launched with a portfolio of decellularized biologics, including Biovance 3L Ocul…
Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon
NEW YORK–(BUSINESS WIRE)–Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), today announced that…
Long-Term Control of NMOSD With Ravulizumab
For neuromyelitis optica spectrum disorder, long-term follow-up with a second-generation complement inhibitor shows an unprecedented level of disease control at 3 years. Medscape Medical News